NCT05557292View on ClinicalTrials.gov

RMC-5552 Monotherapy in Adult Subjects With Recurrent Glioblastoma

PHASE1RecruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

April 3, 2023

Primary Completion Date

April 30, 2030

Study Completion Date

April 30, 2030

Conditions
GlioblastomaRecurrent Glioblastoma
Interventions
DRUG

RMC-5552

Given IV

Trial Locations (1)

94143

RECRUITING

University of California, San Francisco, San Francisco

All Listed Sponsors
collaborator

Revolution Medicines, Inc.

INDUSTRY

collaborator

National Cancer Institute (NCI)

NIH

lead

Nicholas Butowski

OTHER